CG Oncology, Inc. (CGON) Stock Statistics & Valuation Metrics

CG Oncology, Inc. has a market cap or net worth of $5.22B. The enterprise value is $5.20B.

CG Oncology, Inc. has 84,435,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

CG Oncology, Inc.’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.05%.

The current PE Ratio of CG Oncology, Inc. is ―. CG Oncology, Inc.’s PEG ratio is -0.42.

In the last 12 months, CG Oncology, Inc. had revenue of 4.04M and earned -161.00M in profits. Earnings per share was -2.08.

In the last 12 months, operating cash flow was -132.35M and capital expenditures -134.00K, giving a free cash flow of -132.48M billion.

CG Oncology, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

CG Oncology, Inc. upcoming earnings date is May 7, 2026, Before Open (Confirmed).

CG Oncology, Inc. as a current ratio of 24.63, with Debt / Equity ratio of 0.93%

In the past 12 months, CG Oncology, Inc. has paid 0.00 in taxes.

CG Oncology, Inc. EV to EBITDA ratio is -19.96, with an EV/FCF ratio of -24.04.

CG Oncology, Inc. has $742.15M in cash and marketable securities with $7.02M in debt, giving a net cash position of $735.13M billion.

Gross margin is -15.02%, with operating margin of -4722.13%, and net profit margin of -3985.02%.

The average price target for CG Oncology, Inc. is $83.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy